| LISBON -- Whispered concerns about a higher risk of certain cancers linked with incretin therapies for diabetes have become more audible after a debate here between top researchers.
In the hot seat was Peter Butler, MD, of the University of California Los Angeles, who, with colleagues, recently published a paper in Gastroenterology that found higher rates of pancreatitis and pancreatic cancer in patients on either sitagliptin (Januvia) or exenatide (Byetta).
The findings were based on an analysis of data from the FDA's Adverse Event Reporting System (AERS), which is known to have several limitations, as pointed out by debate opponent Michael Nauck, MD, of the Diabetes Center Bad Lauterberg in Harz, Germany.
"There will be a lot of reporting bias," Nauck said during an interview with MedPage Today. "If there is public awareness for certain things, then physicians and others will feel more inclined to report such events to the database."
|
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.